- $17.52m
- -$4.11m
- $11.20m
- 33
- 33
- 33
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.83 | ||
| Price to Tang. Book | 0.83 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.56 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -5.5% | ||
| Return on Equity | 0.04% | ||
| Operating Margin | -10.31% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 16.14 | 0.5 | -2.85 | 11.2 | 1.5 | 1.02 | 132.45% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Directors
- Mahesh Patel CHM (64)
- Nachiappan Chidambaram VPR (52)
- Stephen Hill LED (62)
- John Higuchi DRC (53)
- Jeffrey Fink IND (63)
- Richard Ono IND (68)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 13th, 2011
- Public Since
- March 21st, 2014
- No. of Shareholders
- 87
- No. of Employees
- 16
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 5,350,356
- Address
- 675 S Arapeen Dr Ste 202, SALT LAKE CITY, 84108-1295
- Web
- https://www.lipocine.com/
- Phone
- +1 8019947383
- Contact
- Krista Fogarty
- Auditors
- Tanner LLC
Upcoming Events for LPCN
Lipocine Inc Annual Shareholders Meeting
Q2 2025 Lipocine Inc Earnings Release
Q3 2025 Lipocine Inc Earnings Release
Similar to LPCN
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Lipocine share price?
As of Today at 21:46 UTC, shares in Lipocine are trading at $3.28. This share price information is delayed by 15 minutes.
How has the Lipocine share price performed this year?
Shares in Lipocine last closed at $3.28 and the price had moved by -37.5% over the past 365 days. In terms of relative price strength the Lipocine share price has underperformed the S&P500 Index by -42.33% over the past year.
What are the analyst and broker recommendations for Lipocine?
The overall consensus recommendation for Lipocine is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Lipocine dividend yield?
Lipocine does not currently pay a dividend.
Does Lipocine pay a dividend?
Lipocine does not currently pay a dividend.
When does Lipocine next pay dividends?
Lipocine does not currently pay a dividend.
How do I buy Lipocine shares?
To buy shares in Lipocine you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lipocine?
As of the previous close price of $3.28, shares in Lipocine had a market capitalisation of $17.52m.
Where are Lipocine shares listed?
Here are the trading details for Lipocine:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: LPCN
What kind of share is Lipocine?
Based on an overall assessment of its quality, value and momentum Lipocine is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lipocine share price forecast for 2025?
The analyst consensus target price for shares in Lipocine is $6.75. That is 106.11% above the last closing price of $3.28.
Analysts covering Lipocine currently have a consensus Earnings Per Share (EPS) forecast of -$1.85 for the next financial year.
Find out moreWhat is the trend in the Lipocine share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lipocine. Over the past six months, its share price has underperformed the S&P500 Index by -27.05%.
As of the last closing price of $3.28, shares in Lipocine were trading -23.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lipocine PE Ratio?
The Lipocine PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lipocine?
Lipocine's management team is headed by:
- Mahesh Patel - CHM
- Nachiappan Chidambaram - VPR
- Stephen Hill - LED
- John Higuchi - DRC
- Jeffrey Fink - IND
- Richard Ono - IND